Clinical trial
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With…
NCT02950155 · Fredrik Piehl, Other · Completed
Key facts
| NCT number | NCT02950155 |
|---|---|
| Title | A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis |
| Official title | A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG) |
| Acronym | Rinomax |
| Lead sponsor | Fredrik Piehl, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Myasthenia Gravis |
| Intervention type | Drug |
| Interventions | Rituximab, Sodium Chloride solution |
| Enrollment | 47 |
| Start date | Oct 16, 2016 |
| Primary completion | Jan 30, 2021 |
| Completion | Jan 31, 2022 |
| First posted | Oct 31, 2016 |
| Last update posted | Oct 26, 2024 |
| Countries | Sweden |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: